Published in Oncotarget on July 30, 2014
Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells. J Invest Dermatol (2015) 1.43
Potential Effect of CD271 on Human Mesenchymal Stromal Cell Proliferation and Differentiation. Int J Mol Sci (2015) 0.85
ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. EMBO Mol Med (2016) 0.83
Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib. Cell Discov (2015) 0.78
NFATc2 is an intrinsic regulator of melanoma dedifferentiation. Oncogene (2015) 0.76
Cancer Stem Cells (CSCs) in Melanoma: There's Smoke, But Is There Fire? J Cell Physiol (2017) 0.75
In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells. Oncol Rep (2017) 0.75
Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells. Clin Exp Metastasis (2016) 0.75
The Neurotrophin Neuritin1 (cpg15) is involved in melanoma migration, attachment independent growth, and vascular mimicry. Oncotarget (2016) 0.75
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
Identification and expansion of human colon-cancer-initiating cells. Nature (2006) 24.44
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
Identification of cells initiating human melanomas. Nature (2008) 8.28
Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell (2011) 7.30
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature (2010) 5.05
Prospective identification, isolation by flow cytometry, and in vivo self-renewal of multipotent mammalian neural crest stem cells. Cell (1999) 4.54
Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell (2010) 3.70
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res (2005) 3.52
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res (1997) 2.98
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature (2011) 2.96
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev (2006) 2.87
Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res (2010) 2.43
Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol (2013) 2.35
Target for cancer therapy: proliferating cells or stem cells. Leukemia (2006) 2.15
The WNT/Beta-catenin pathway in melanoma. Front Biosci (2006) 2.09
Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res (2011) 2.08
Expression of nodal, lefty-a, and lefty-B in undifferentiated human embryonic stem cells requires activation of Smad2/3. J Biol Chem (2004) 2.03
Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene (2011) 1.83
Cancer stem cell and cancer stemloids: from biology to therapy. Cancer Biol Ther (2007) 1.74
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells (2012) 1.70
Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling. J Biol Chem (2002) 1.59
LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell (2012) 1.49
Identification of the IFITM family as a new molecular marker in human colorectal tumors. Cancer Res (2006) 1.44
Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene (2011) 1.38
Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res (2009) 1.38
MAP kinase signaling and inhibition in melanoma. Oncogene (2012) 1.35
Neoplasms, differentiations and mutations. Am J Pathol (1974) 1.30
Glycogen synthase kinase 3beta is activated by cAMP and plays an active role in the regulation of melanogenesis. J Biol Chem (2002) 1.27
Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Res (2010) 1.24
Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle (2008) 1.20
BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol (2004) 1.16
Cancer stem cells: markers or biomarkers? Cancer Metastasis Rev (2008) 1.15
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. J Clin Oncol (2013) 1.11
SRY-box containing gene 17 regulates the Wnt/β-catenin signaling pathway in oligodendrocyte progenitor cells. J Neurosci (2011) 1.10
Regulation of melanocyte pivotal transcription factor MITF by some other transcription factors. Mol Cell Biochem (2011) 1.03
The emerging picture of the mouse mammary stem cell. Stem Cell Rev (2007) 1.03
BRAF mutations in conjunctival melanoma. Invest Ophthalmol Vis Sci (2004) 1.00
Activated MAPK/ERK kinase (MEK-1) induces transdifferentiation of pigmented epithelium into neural retina. Dev Biol (2002) 0.99
Expression and functional role of CRIPTO-1 in cutaneous melanoma. Br J Cancer (2011) 0.96
Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype. Oncotarget (2013) 0.92
Cripto-1 enhances the canonical Wnt/β-catenin signaling pathway by binding to LRP5 and LRP6 co-receptors. Cell Signal (2012) 0.92
Sox17 modulates Wnt3A/beta-catenin-mediated transcriptional activation of the Lef-1 promoter. Am J Physiol Lung Cell Mol Physiol (2010) 0.88
Leukemia stem cells. Ann Hematol (2010) 0.87
Modulation of the Wnt/beta-catenin pathway in human oligodendroglioma cells by Sox17 regulates proliferation and differentiation. Cancer Lett (2013) 0.85
The significance of a Cripto-1 positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics. Cell Cycle (2013) 0.83